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The aim of this review was to identify factors predicting actual or intended adherence 
to antivirals as treatment or prophylaxis for influenza. Literature from inception to 
March 2015 was systematically reviewed to find studies reporting predictors of adher-
ence to antivirals and self- reported reasons for non- adherence to antivirals. Twenty- 
six studies were included in the review; twenty identified through the literature search 
and six through other means. Of these studies, 18 assessed predictors of actual adher-
ence to antivirals, whereas eight assessed predictors of intended adherence. The most 
commonly found predictor of, and self- reported reason for, non- adherence was the 
occurrence of side effects. Other predictors include perceptions surrounding self- 
efficacy, response efficacy and perceived personal consequences as well as social 
influences of others’ experiences of taking antivirals. Predictors identified in this 
review can be used to help inform communications to increase adherence to antivirals 
in both seasonal and pandemic influenza.
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1  | INTRODUCTION
In April 2009, a new strain of influenza virus was detected in humans 
(influenza A(H1N1)pdm09). The illness, commonly referred to as 
“swine flu,” was first identified in Mexico and spread rapidly around 
the globe. The World Health Organization (WHO) declared pandemic 
phase 5 on 29 April 2009 and raised this alert to pandemic phase 6, 
the highest of the WHO pandemic ranks, on 11 June 2009.
Oseltamivir phosphate (Tamiflu®) is an antiviral medication that is 
used as prophylaxis and treatment for influenza, and was prescribed 
widely during the 2009/2010 swine flu pandemic. As a treatment, it 
does not cure swine flu, but shortens the duration of symptoms.1,2 
Within the United Kingdom, total expenditure on oseltamivir was 
estimated to be £160.4 million in 2009–2010, with 2.4 million units 
of oseltamivir “consumed” between 2009/2010 and 2012/2013, the 
majority of these during the pandemic.3
In an effort to gauge oseltamivir adherence in one area of the 
UK during the pandemic, Singer et al.4 measured levels of the active 
metabolite of oseltamivir in wastewater. When comparing these levels 
with the number of prescriptions collected, adherence was estimated 
to be in the range of 45%–60%. The repercussions of non- adherence 
to antiviral medication are widespread, including the monetary cost of 
unused antivirals,4 a longer duration of absenteeism from work and 
the potential implication of more drastic measures such as school clo-
sures, household quarantine and restrictions on travel. In the UK, the 
cost of school closure alone is estimated at £0.2–£1.2 billion.5 Other 
health implications of non- adherence to antivirals include possible 
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increase in future antiviral resistance and the possibility of misuse 
leaving a shortage of supply.4
There are many reasons why people may choose not to adhere 
to their antiviral medication as prescribed. Research into medication 
adherence has suggested that reasons for non- adherence include 
social and economic factors (such as social support, family/ caregiver 
factors and socio- economic status), therapy- related factors (such as 
the presence of adverse effects, duration of treatment and drug effec-
tiveness), patient- related factors (such as age, gender and education) 
and condition- related factors (such as the presence of symptoms and 
disease severity), amongst others.6 To the best of our knowledge, 
there is no systematic review describing factors affecting adherence 
to antiviral medication for influenza specifically.
Given that adherence is a complex behavioural process,7 the 
successful implementation of interventions that promote adherence 
requires a thorough understanding of the factors associated with 
that behaviour. The Capability, Opportunity and Motivation (COM- B) 
framework was developed from existing theories of behaviour 
change.8 In essence, the framework hypothesises that the interaction 
between capability (C), opportunity (O) and motivation (M) causes the 
performance of behaviour (B) and can provide a framework for under-
standing why a desired or recommended behaviour is not performed. 
Capability is defined as the individual’s psychological and physical 
capacity to engage in the activity and includes having the necessary 
knowledge and skills; Opportunity is defined as all the factors that lie 
outside the individual that make the behaviour possible or prompt 
it; and Motivation is defined as the mental processes that energise 
and direct behaviour, not just goals and conscious decision- making 
but also habitual processes and emotional responses. The COM- B 
approach has recently been applied to medication adherence.9 It is 
able to account for a wide range of factors affecting adherence and 
to inform behaviour change interventions that can be used to guide 
healthcare practitioners involved in the care of non- adherent patients.
To inform policy regarding the distribution of and communication 
about antivirals as treatment or prophylaxis in seasonal and future 
pandemic influenza, we conducted a systematic review to investigate 
factors associated with adherence and non- adherence to antiviral 
medication for influenza. The outcome measures of this review includ-
ed predictors of adherence and non- adherence, and self- reported rea-
sons for non- adherent behaviours.
2  | METHOD
The review was conducted in accordance with the PRISMA guide-
lines,10 using systematic methods to identify and select studies, and 
assess their risk of bias. No formal protocol exists for this review.
2.1 | Search strategy
We searched EMBASE, MEDLINE, PsycINFO and the Web of Science 
Core Collection from inception to 26 March 2015, using combinations 
of terms relating to antivirals (e.g. antiviral, Tamiflu, oseltamivir, Relenza, 
zanamivir), influenza (e.g. pandemic, influenza, H1N1, H5N1) and adher-
ence (e.g. adherence, uptake, compliance). There was no limit on publica-
tion date imposed. Where possible, databases were also searched using 
MeSH headings. We also undertook reference tracking to identify fur-
ther papers for inclusion. Other articles were located through previous 
non- systematic searches carried out by members of the research team.
2.2 | Inclusion criteria
Eligibility criteria for inclusion in the systematic review were as follows:
Participants: Studies were included if they asked people whether 
they took antivirals as either treatment or prophylaxis for influenza or 
whether they intended to take antivirals as treatment or prophylax-
is for influenza. Participants could be drawn from the general public, 
patient groups or specific occupational groups.
Predictors/Exposures: We only included studies if they assessed 
demographic or psychosocial predictors of adherence to antivirals in 
the context of influenza or if they assessed self- reported reasons for 
adherence or non- adherence to a course of antivirals.
Outcomes: Studies were included if they reported actual or intend-
ed adherence to antivirals, which were intended as either treatment or 
prophylaxis for pandemic, avian or seasonal influenza.
Study reporting: All study designs, aside from those published 
only as conference papers, editorials or abstracts, were included. For 
 pragmatic reasons, we only accepted papers published in English.
2.3 | Data extraction
For every included paper, we tabulated details relating to the author, 
date of publication, influenza virus, country, sample size, methodol-
ogy, adherence with antivirals, length of course of antivirals, and 
 reasons for, and predictors of, non- adherence.
2.4 | Data synthesis
Where possible, we grouped study results together depending on 
whether they related to actual vs intended adherence, antivirals pre-
scribed as a treatment vs antivirals prescribed as a prophylaxis and 
pandemic (influenza A(H1N1)pdm09) vs non- pandemic situations. In 
practice, it was not always possible to make these subdivisions due to 
a limited amount of data being available.
A meta- analysis of the data was not planned, because we expected 
that the literature would be too heterogeneous. Instead, we carried 
out a narrative synthesis of the data. No general consensus exists on 
the best methodological approach to the narrative synthesis of data.11 
In this review, we created a comprehensive list of predictors of actual 
and intended adherence to antivirals that have been studied to date. 
Effect sizes were not synthesised.
2.5 | Risk of bias
Risk of bias was determined according to an adaptation of the 
Scottish Intercollegiate Guidelines Network (SIGN) critical appraisal 
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methodology checklist for cohort studies12 and supplemented by 
relevant items from the Cochrane Collaboration’s Risk of Bias tool.13 
Table 1 shows the criteria used in the assessment.
2.6 | Procedure
LS and VJ developed and conducted our literature search. Studies were 
screened by LS, and data extraction, assessment of risk of bias and data 
synthesis were carried out independently by LS and DD with advice from 
JP, GJR and JW. Any discrepancies were resolved through discussion.
3  | RESULTS
Figure 1 illustrates the results of our literature search. We identified 
1014 citations through our database search, of which twenty fulfilled 
the inclusion criteria. Six additional articles were identified through 
other search engines such as ScienceDirect and in review articles on 
the topic area. For one of our included studies,14 additional information 
was obtained from the author (Phern- Chern, personal communication).
3.1 | Study characteristics
Eighteen articles assessed actual adherence to antiviral medication, 
while eight assessed intended adherence. The studies spanned thir-
teen countries (Australia, Brunei, Canada, Cyprus, Hong Kong, Israel, 
Japan, Madagascar, Netherlands, Norway, UK, USA and Singapore) 
and included samples of healthcare workers, military personnel, preg-
nant or recently pregnant women, poultry farmers, end- stage renal 
patients, school children and staff as well as the general public. All 
but three studies investigated pandemic influenza (actual influenza 
A(H1N1)pdm09 or hypothetical scenarios), with other studies inves-
tigating influenza H5N1,15 H7N316 and seasonal influenza.17 The 
majority of studies were cross- sectional, with one RCT,18 and two 
qualitative studies.19,20 All but one study18 investigated adherence 
with antivirals via self- report. All studies investigated predictors of 
actual or intended adherence to oseltamivir; no studies included in 
the review investigated predictors of adherence to zanamivir (trade 
name “Relenza”) or other antivirals such as amantadine. Tables 2 and 
3 provide information about the samples and methods of the included 
studies, which addressed actual and intended adherence, respectively. 
Tables 4 and 5 provide adherence rates in each study, together with 
self- reported reasons for, and predictors of, actual and intended non- 
adherence. Where reported by individual studies, numerical data for 
significant predictors of adherence are stated in Tables 4 and 5.
3.2 | Assessment of risk of bias
We identified serious methodological flaws in several of the included 
studies. Studies showing higher risk of bias (selection bias, detection 
bias, reporting bias and other sources of bias) are identified in Table 4 
and 5. Many studies did not clearly report response rates16–18,20–31 
or eligibility criteria to ensure that the sample was representa-
tive.14,16,17,19,20,24,25,28,30–36 Additionally, four studies had small sam-
ple sizes.18,24,30,32 Multiple studies lacked clearly defined outcom
es14,16–18,22–25,27,28,30,32–35,37 and all but two studies18,19 lacked valid 
and reliable methods of outcome measures, both factors contributing to 
higher potential detection bias. Reporting bias was found in studies that 
did not report confidence intervals15,17,18,23–25,30–32,35 and which did 
not carry out appropriate analyses of association between adherence 
rates and potential predicting factors.17,23–25,31,32,37,38 Other sources 
of bias included the fact that none of the studies reported a sample size 
calculation. Main potential confounders were not taken into account in 
ten studies.17,18,23–25,29,31–33,37 Fourteen studies also did not address 
appropriate or clearly focused questions.14,16–18,23–25,29–33,36,37
3.3 | Actual adherence
In studies investigating actual adherence with oseltamivir, adherence 
ranged from 30% to 88.8%.38 Most studies reported a high overall 
adherence in the range of 70%–89%. Eight studies investigated adher-
ence to antivirals only as a preventative measure (six in the context of 
influenza A(H1N1)pdm09), three investigated adherence to antivirals 
only as a therapeutic measure (two in relation to influenza A(H1N1)
pdm09), five investigated predictors of adherence to antivirals as both 
treatment and prophylaxis (all in reference to influenza A(H1N1)pdm09), 
and two studies did not report the reason for antiviral prescription.
TABLE  1 Criteria for risk of bias assessment
Code Bias Item(s)
A Selection bias The study indicates how many of the people asked to take part did so
A clear definition of source of population and clear eligibility criteria for selection of subjects are used, to ensure 
the sample is representative
B Detection bias The outcomes are clearly defined
The method of outcome assessment is valid and reliable
C Reporting bias Confidence intervals have been provided
Appropriate statistical analyses have been carried out
The main potential confounders are identified and taken into account in the design and analysis
D Other bias A power calculation is reported. If not, sample size is small, medium or large (Small, n=30–59; medium, 
n=60–150; large, n=150+)
The study addresses an appropriate and clearly focused question
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3.3.1 | Antivirals as prophylaxis
When antivirals were prescribed as prophylaxis for influenza A(H1N1)
pdm09, the only demographic predictor of adherence was sex, with 
male students being more likely to take oseltamivir than female stu-
dents.39 Other predictors included an earlier time in the pandemic,18 
country of study (higher adherence in students studying in Singapore 
than those studying in the United States),39 previous compliance with 
other precautionary advice about pandemic flu,39 beliefs that the rec-
ommended preventative measures were necessary39 and having dis-
cussed taking oseltamivir with someone who had not experienced side 
effects.30 Where antivirals were prescribed as prophylaxis for avian 
influenza (H7N3), having had direct contact with infected poultry was 
a significant predictor for adherence to antivirals.16
Where self- reported reasons for non- adherence to antivirals as 
prophylaxis for influenza A(H1N1)pdm09 were stated, occurrence 
of adverse events was the most commonly reported reason for the 
discontinuation of oseltamivir.18,30,31,38 Fear (cause unspecified) was 
also given as a reason for discontinuation of oseltamivir in end- stage 
renal failure patients,38 as was not wanting to take it.38 For those tak-
ing oseltamivir in conjunction with their work, there being no direct 
contact with the virus was given as a reason for non- adherence.30 
Forgetting to take oseltamivir31,38 and losing tablets38 were also given 
as reasons for discontinuation.
Where self- reported reasons for non- adherence to antivirals as 
prophylaxis in non- pandemic situations were presented, the presence 
of adverse events was given as a reason for discontinuation of antivi-
rals for influenza H5N115 as was not receiving enough tablets.15 For 
those taking oseltamivir as a result of avian influenza outbreak (H7N3) 
at work, not being in direct contact with the virus was a reason given 
for discontinuation of oseltamivir.16
3.3.2 | Antivirals as treatment
No predictors of adherence were found when antivirals were pre-
scribed only as treatment for influenza A(H1N1)pdm09, nor were 
any statistically significant predictors of adherence found in non- 
pandemic situations.
F IGURE  1 Literature search
Records identified through search 
(n = 1014)
Titles screened 
(n = 632)
Abstracts screened 
(n = 165)
Full-texts screened for eligibility 
(n = 84)
Studies included 
(n = 20)
Number excluded after excluding duplicates 
(n = 382)
Number excluded after screening titles 
(n = 470)
Number excluded after screening abstracts
(n = 69)
Full-text articles excluded (n = 64). Reason for 
exclusions:
• No mention of predictors of adherence
(n = 32)
• No novel data (n = 15)
• No reference to antivirals (n = 8)
• Conference abstract, editorials (n = 6)
• Not in English (n = 3)
Articles found in references and by other 
means (n = 6)
Total studies included 
(n = 26)
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Where self- reported reasons for non- adherence to antivirals as 
treatment for influenza A(H1N1)pdm09 were stated, occurrence 
of adverse events was the most commonly reported reason for 
the discontinuation of oseltamivir.24,25 The fear of developing side 
effects was also sufficient to stop people from beginning oseltami-
vir. Perception of clinical improvement was given as a self- reported 
reason for stopping treatment with oseltamivir. Self- reported rea-
sons for non- adherence to antivirals as treatment in non- pandemic 
situations (seasonal influenza) included the presence of adverse 
events.15
3.3.3 | Antivirals as treatment and prophylaxis
One study identified taking a lower, prophylactic, daily dose rather 
than a higher, treatment daily dose as being a predictor of adherence 
to antivirals for influenza A(H1N1)pdm09.36 Two studies investigating 
antivirals prescribed both as treatment and as prophylaxis for influenza 
A(H1N1)pdm09 identified significant predictors of adherence, but 
unfortunately the studies did not differentiate between predictors of 
adherence to antivirals as treatment vs prophylaxis. In these cases, the 
presence of adverse effects,29 age, with higher adherence to antivirals 
for influenza A(H1N1)pdm09 in those aged <40, and the presence of 
adverse effects were identified as predictors of adherence.
Self- reported reasons for discontinuation of antivirals for influ-
enza A(H1N1)pdm09 in studies that did not differentiate between 
treatment and prophylactic use of antivirals included the presence of 
adverse events29,36 as well as the perception that antivirals were not 
effective.23,29 People also stopped taking oseltamivir because they 
had medical advice to stop taking the drug,36 forgot to take it28,29 and 
because they had difficulty swallowing the tablets.36 The perception 
that there was a greater risk of developing side effects after having 
taken oseltamivir than there was a risk of catching influenza A(H1N1)
pdm0923 also stopped people from beginning to take antivirals for 
influenza A(H1N1)pdm09.
TABLE  3 Methods of included studies measuring intended adherence
Citation Study design Virus
Location (time of 
data collection)
Number of participants (mean 
age in years)
Cohort (% of sample 
male)
Bults et al.21 Web based 
cross- sectional 
surveys with 
one follow- up 
survey
Pandemic influenza 
A(H1N1)
Netherlands 
(April–August 
2009)
Survey 1 (May 2009), n=456; 
Survey 2 (June 2009), n=478; 
Follow- up of survey 1 & 2 
(August 2009), n=934 (Age at 
follow- up: 18–29 y, 12.3%; age 
30–49 y, 36.3%; 50+ y, 52%)
Dutch adult population—
general public (52%)
Ibuka et al.22 Cross- sectional 
study
Pandemic influenza 
A(H1N1)
USA (April–May 
2009)
N=1290 (18–29 y, 13%; 
30–39 y, 19%; 40–49 y, 21%; 
50–64 y, 28%; 65+, 18%
US adult population—gen-
eral public (49%)
Lynch et al.20 Qualitative, 
focus groups
Pandemic influenza 
A(H1N1) and 
seasonal influenza
USA (September 
2009)
N=144 (18–24 y, 26%; 25–34 y, 
62%; 35–44 y, 12%)
Pregnant or recently 
pregnant—within 6 mo 
post- partum—women 
(0%)
Masuet- Aumatell 
et al.26
Cross- sectional 
study
Pandemic influenza 
A(H1N1)
London, UK 
(September 
2009)
N=100 (32) Travellers attending a UK 
travel clinic (43.8%)
Yap et al.14; 
Phern- Chern, 
personal 
communication
Cross- sectional 
study
Pandemic influenza 
A(H1N1)
Singapore 
(August–
October 2009)
N=1063 (21.4) Singapore military: 4.4% 
laboratory- confirmed 
cases; 23.0% contacts; 
31.1% healthcare 
workers; 41.5% general 
servicemen. (95.8%)
Quinn et al.27 Cross- sectional 
study
Pandemic influenza 
A(H1N1)
USA (June–July 
2009)
N=1543 (46.3) Members of US general 
public aged 18 or over 
(48.2%)
Rubinstein 
et al.19
Semistructured 
interviews and 
focus groups 
with samples 
of the general 
public
Hypothetical 
pandemic 
scenarios
London and 
Southampton 
(November 
2013–March 
2014)
N=71 (16–35, n=21 (29.6%); 
36–64, n=20 (28.2%); 65+ y, 
n=30 (42.3%)
Diverse samples of 
general public with 
different at- risk status 
(32.4%)
Seale et al.35 Cross- sectional 
study
Influenza pandemic Sydney, Australia 
(June–October 
2007)
N=1079 (18–30, n=338 (31.3%); 
31–40, n=280 (25.9%); 41–50, 
n=247 (22.9%); 51+, n=186 
(17.2); not specified, 28 (2.6%)
Healthcare workers 
(22.7% male; 2.5% 
unspecified)
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Studies which did not specify at all the reason why antivirals were 
prescribed as treatment or prophylaxis for influenza A(H1N1)pdm09 
also identified fear of developing side effects as a reason not to begin 
oseltamivir and perception of clinical improvement as a reason for 
stopping oseltamivir.
3.4 | Intended adherence
Studies investigating predicted adherence with antivirals found an 
intended adherence rate ranging from 43.5%20 to 85.5% (Phern- 
Chern, personal communication). All studies reported intended 
adherence to antivirals in pandemic situations, but one also investi-
gated hypothetical seasonal flu situations.20 All studies found signifi-
cant predictors of adherence. Female sex was associated with higher 
intended adherence to antivirals for oneself22 and intention to divert 
antivirals to family members.35 Older age was also predictive of 
adherence26,27 as was Malay ethnicity in the Singaporean military14 
and ethnicity in the acceptance of antivirals for the self and for one’s 
children in the US population.27 Household composition was also 
associated with intended adherence to antivirals in the general popu-
lation, but with opposing results in different countries. In the United 
States, larger household size was a predictor of intended adherence 
to antiviral medication for the treatment of pandemic influenza,22 
whereas in the Netherlands, intention to take antivirals as prophy-
laxis was associated with not having children in the household.21 
Other predictors of intended adherence to antivirals included higher 
risk perception of catching pandemic influenza,21,22 knowledge of 
pandemic influenza14 and its associated risks26 and perceived per-
sonal consequences of influenza27 as well as amount of information 
received about pandemic influenza,21 increased attention to informa-
tion21 and information seeking behaviours.22 In the United States, 
trust in the government was also associated with acceptance of 
antivirals for oneself and one’s children.27 Higher levels of anxiety, 
self- efficacy and response efficacy,21 worry about antivirals27 and a 
positive attitude towards influenza prevention26 were also predictive 
of intended adherence to antivirals, as were compliance with other 
preventive measures22,26,35 and having previously accepted the flu 
vaccine.27
Two studies investigating intended adherence used qualitative 
methods. The first investigated pregnant and recently pregnant 
women’s perceptions about both seasonal and pandemic influen-
za.20 They found that unfamiliarity with antiviral medicines, concerns 
about potential side effects for the foetus and the pandemic nature 
of influenza (over seasonal influenza) were predictors for adherence 
to antiviral medication. The second study19 reported the views of 
diverse samples of the general public with different at- risk status 
within the framework of the COM- B model of behaviour change.8 
Within this context, psychological capability (e.g. knowledge of the 
pandemic), automatic motivation (e.g. being vaccinated for season-
al flu), reflective motivation (e.g. beliefs about the effectiveness and 
safety of the medicine, health identity), physical opportunity (e.g. 
access to treatments and professional advice) and social opportu-
nity (e.g. trust in recommendations from health professionals) were 
identified as being important for adherence to a course of antiviral 
medication.
4  | DISCUSSION
Identifying predictors of adherence can help to inform areas which 
can be targeted to improve adherence further still. Attempts to iden-
tify demographic predictors of adherence have given mixed results, 
with male sex being found as a predictor for actual adherence in sum-
mer school students39 and female sex being found as a predictor of 
intended adherence in the Singaporean military.22 Age was also a 
predictor of actual adherence with oseltamivir during the 2009/2010 
influenza pandemic, with higher adherence seen in people with an 
influenza diagnosis in Norway aged under 40.37 In contrast, older age 
was found to predict intended adherence to antivirals amongst a rep-
resentative sample of the US population27 and travellers attending a 
UK travel clinic.26 This may be because older adults are at a higher risk 
of developing complications from influenza and have a higher prob-
ability of having previously had the flu vaccine, and so this portion of 
the population may be more used to accepting pharmaceutical inter-
ventions as personal protection.
There were no major qualitative differences between predictors of 
adherence to antivirals as treatment or prophylaxis for influenza. Any 
minor differences are likely because prophylactic courses of antivirals 
tended to be longer than treatment courses, with one study in particu-
lar indicating a 20- week prophylactic prescription period.18 Due to the 
lack of major qualitative differences between predictors, results for 
predictors of adherence to antivirals as treatment and prophylaxis are 
discussed together in the context of the wider literature. Furthermore, 
only three studies investigated predictors of actual adherence to anti-
virals and self- reported reasons for discontinuation of antivirals in 
non- pandemic influenza situations.15–17 The results of these three 
studies did not differ qualitatively for pandemic and non- pandemic 
influenza and results from pandemic and non- pandemic studies are 
therefore also discussed together.
The most commonly found predictor of actual and intended 
adherence, and reason given for non- adherence, was the incidence 
of adverse side effects, with studies indicating that the fear of side 
effects was enough to stop people from beginning a course of osel-
tamivir. Members of the public may perceive the incidence of side 
effects from antivirals to be considerably higher than is actually the 
case. According to clinical trial data, the most common side effect of 
oseltamivir as a treatment for influenza is nausea (without vomiting) 
affecting 10% people, with the most common side effect of oseltami-
vir when used as prophylaxis being headache, affecting 18% people. 
However, approximately half the Singaporean military surveyed per-
ceived adverse side effects to be caused by oseltamivir (Phern- Chern, 
personal communication). Correcting misperceptions about the rates 
of side effects associated with oseltamivir may help to boost rates of 
adherence.
Other non- demographic predictors of adherence largely fell into 
categories identified by the COM- B model of behaviour change8(see 
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Table 6), in line with results from Jackson et al.40 The COM- B model 
of behaviour change identifies three components—capability, moti-
vation and opportunity—all of which are necessary to target when 
attempting to initiate behaviour change. Capability can be further 
divided into physical and psychological capability, motivation into 
reflective and automatic motivation, and opportunity into physical 
and social opportunity.8 With reference to the particular predictors 
of adherence identified in this review, knowledge about influenza, 
amount of information about influenza and increased attention to 
information about influenza could be categorised within psychologi-
cal capability. For example, one predictor found to be associated with 
adherence to antivirals was knowledge about pandemic flu. Although 
knowledge about influenza A(H1N1)pdm09 was moderate,41 there 
have been calls for education about oseltamivir because it being con-
fused with a vaccine for influenza.42 Analysis of the content of one 
year’s worth of UK newspaper articles relating to the 2009/2010 
influenza pandemic found that approximately 10% of articles men-
tioned that oseltamivir helped symptoms of influenza A(H1N1)
pdm09.43 This proportion is relatively low, potentially affecting peo-
ples’ perceptions of oseltamivir, in turn affecting compliance rates. 
For this reason, it may be important to educate the general public 
about the risks of influenza, both seasonal and pandemic as well as 
ensuring clarity when delivering messages about who is recommend-
ed for pharmaceutical interventions.
Risk perception, including perceived severity of and vulnerability 
to the outbreak, was also found as a predictor of intended adher-
ence to antiviral medication. When communicating with the public, 
the perception of the overall severity of the outbreak should not be 
overlooked, as it influences the adoption of behavioural changes.44 
It has been suggested that during the pandemic, the general public 
were complacent and passive, making them vulnerable to influenza 
A(H1N1)pdm09 through their lack of uptake of safety behaviours.45
In terms of motivation, perception of the risk of catching influen-
za, perception of the severity of influenza, perceived personal con-
sequences of influenza, attitude towards the prevention of influenza 
beliefs associated with the necessity of precautionary behaviours and 
concern about the safety, side effects and effectiveness of the pharma-
ceutical recommendation could be classified as reflective motivation. 
Automatic motivation comprises emotions of fear (towards antivirals 
themselves and side effects elicited by antivirals), and higher anxiety 
levels, as well as previous engagement in precautionary behaviours 
including previous acceptance of the influenza vaccine. Social oppor-
tunity includes predictors such as trust in the government and speak-
ing to someone who had previously experienced side effects when 
taking antivirals and physical opportunity incorporates losing the pills 
or not having enough pills. The psychological capability aspect of the 
COM- B model is reflected in forgetting to take the pills, whereas the 
physical capability aspect could be seen in having difficulty swallowing 
them.
Predictors that are less easy to categorise within the COM- B mod-
el were also identified. One study identified time in the study peri-
od as a predictor of adherence to oseltamivir with participants being 
more adherent in the first 10 weeks of the study than in the second 
10 weeks. This is possibly due to changing perceptions of the risk of 
contracting flu as the pandemic season continued and concern about 
the effects of long- term prophylaxis (both linked to reflective motiva-
tion in the COM- B model) as well as the increasing burden in everyday 
life of continuing to take oseltamivir prophylaxis daily (linked to physi-
cal capability in the COM- B model). Higher adherence with lower daily 
doses of oseltamivir was also found as a predictor of adherence and 
could be due to the perception that taking less of a drug is safer and 
better tolerated, but this speculative interpretation should be treated 
with caution.
4.1 | Limitations of the reviewed literature
Overall, the studies reviewed left room for improvement in meth-
odological rigour. Of the 26 included studies, nine showed high risk 
of selection bias, fifteen showed high risk of detection bias, fourteen 
showed high risk of reporting bias and seven showed high risk of other 
sources of bias (see Tables 4 and 5). Studies of particular concern had 
small sample sizes (<60 participants),18,24,30,32 limited robustness of 
outcome assessment and no analysis of association between adher-
ence rates and potential predicting factors.17,23,24,32 These sources 
of bias could have had a profound impact on the results of the indi-
vidual studies. For instance, the fact that no studies reported having 
TABLE  6 Predictors of uptake of antivirals identified in relation to the COM- B model of behaviour change
Capability Motivation Opportunity
Psychological 
• Knowledge of the virus
• Amount of information received about the virus
• Information seeking behaviours
• Increased attention to information about virus
• Forgetting
Reflective 
• Perception of virus and associated risks
• Perception of antivirals and associated risks (response efficacy)
• Belief of necessity of precautionary behaviour
• Self-efficacy
• Perceived personal consequences of flu
• Positive attitude towards prevention of flu
Physical 
• Losing pills
• Not having enough 
pills
Physical 
• Difficulty swallowing pills
Automatic 
• Habitual behaviour of previous compliance with precautions
• Emotion—fear (of antivirals, and of side effects of antivirals)
• Emotion—anxiety
Social 
• Trust in government
• Speaking to someone 
who has experienced 
side effects previously
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conducted a power calculation suggests that predictors of adherence 
that may exert medium to small effects may have been missed.
Other methodological limitations of the studies reviewed include 
that that self- report measures of adherence were used in all but one 
of the 26 studies reviewed, in which objective measures of adherence 
such as pill counts and the use of electronic medicine vial caps were 
used. In general, self- report measures of adherence tend to result in 
higher estimates of adherence compared with objective measures.46,47
Although we did not systematically search for rates of adherence to 
antivirals and therefore any interpretation of adherence rates should be 
taken with caution, it is interesting to note that in some cases intended 
adherence rates to antivirals were lower than actual adherence. This 
is surprising as although people may intend to carry out a particular 
health behaviour, they do not necessarily always do so; this is termed 
the “intention–behaviour gap”.48 However, an explanation for this pat-
tern may lie in the populations of participants assessed in the studies 
reviewed. Many of the studies reporting actual adherence to oseltami-
vir were conducted in specified populations who were prescribed osel-
tamivir as part of their job, either to protect themselves from catching 
influenza (e.g. poultry farmers15,16) or to protect already at- risk patient 
populations (e.g. healthcare workers18,30). Other studies included popu-
lations of people who were already ill or at- risk from influenza (e.g. renal 
patients38) or who had been in close contact to a confirmed case of 
pandemic influenza (school studies23,29,31,33,36,39), with all participants 
enrolled in these studies having already been prescribed antivirals.
Conversely, three studies investigating intended adherence to 
oseltamivir were conducted in samples of the general population in 
different countries (representative samples of the Netherlands21 and 
United States22,27). Amongst these participants, there will be a large 
proportion of people for whom antivirals would not be prescribed in 
the hypothetical scenarios set out by the studies, or who may fit into 
“at- risk” populations but who may be unaware of the recommenda-
tions relating to antivirals.49,50 There may also be a number of people 
who display symptoms of flu, but who do not present to health care 
providers. Such people would not be identified or included in research 
investigating actual adherence rates to antivirals. In this way, studies 
investigating actual adherence in the subset of patients who pres-
ent to primary care may overestimate likely adherence in the general 
population.
The difference between adherence defined as collecting and then 
finishing a course of antivirals, and adherence defined as completing 
a course once the first tablet has been taken, can also be demonstrat-
ed by one of the papers in this review.39 In this study, all students 
attending a summer school were offered oseltamivir without cost. Of 
these students, only 47.6% students picked up oseltamivir, of whom 
70.2% took the medication. This means that 33.4% of students took 
oseltamivir, a much lower number than an adherence rate calculated 
from only those who picked up the drug.
4.2 | Limitations of the review
To the best of our knowledge, this is the first systematic review inves-
tigating predictors of antiviral adherence. One particular strength of 
this review is that studies were not limited only to influenza A(H1N1)
pdm09, but also included predictors of adherence of antivirals during 
seasonal influenza, and so can help inform routine communications 
with the public.
The limitations of this systematic review are inherently bound to 
the methodologies of the original research studies reviewed. Studies 
used very different methodologies to assess adherence and predictors 
of adherence to antivirals in a wide range of participant populations. 
In addition to this, differences in definitions of adherence and length 
of recommended use of antivirals (spanning 5 days to 20 weeks) 
between studies further limited interpretation of results. Although the 
presence of these factors has broadened the results, with predictors 
related to time within the study being identified, the influence of these 
factors made comparisons between studies difficult. Due to this wide 
variation in studies reviewed, meta- analysis of results was not appro-
priate. The poor reporting of effect sizes for individual studies was also 
problematic.
Another limitation of the review is that the neither the grey liter-
ature, nor unpublished papers were searched for pragmatic reasons, 
nor did we undertake forward citation tracking; articles not written in 
English and conference abstracts were also excluded. This increases 
the likelihood that some research into predictors of adherence to anti-
virals has been overlooked. The nature of publication bias, in which 
studies finding a statistically significant result are more likely to be 
published, suggests that any literature that we missed is unlikely to 
have found significant predictors of adherence.
One further thing to consider when interpreting the results of 
this review is that there was a wide variety of populations includ-
ed, from poultry workers, to renal patients and that results were 
not subcategorised according to population type. Had these further 
distinctions been made, there would have been few articles in each 
group.
5  | CONCLUSIONS
The most consistently found predictor of actual or intended adher-
ence and reason given for non- adherence to antivirals was the inci-
dence of side effects. Other predictors can help to inform future 
strategies to increase adherence to antivirals. In particular, increas-
ing knowledge about the risks of influenza, correcting misperceptions 
about side effects and putting into perspective the risks of antivirals 
may help to increase future adherence to antivirals.
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